Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
IsraelIPO:
12 April 2011Website:
http://www.inspiremd.comNext earnings report:
06 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 16 Nov 2024 00:34:58 GMTDividend
Analysts recommendations
Institutional Ownership
NSPR Latest News
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –
CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022.
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial
InspireMD Inc. (NASDAQ:NSPR) will be hosting their Q1 2024 Results Conference Call on May 14, 2024 at 8:30 AM ET. Present on the call will be Chuck Padala, Marvin Slosman, and Craig Shore. Participants on the call include Adam Maeder from Piper Sandler. Welcome to the InspireMD First Quarter 2024 Earnings Call. Please note that all participants are currently in listen-only mode.
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024.
What type of business is InspireMD?
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
What sector is InspireMD in?
InspireMD is in the Healthcare sector
What industry is InspireMD in?
InspireMD is in the Medical Devices industry
What country is InspireMD from?
InspireMD is headquartered in Israel
When did InspireMD go public?
InspireMD initial public offering (IPO) was on 12 April 2011
What is InspireMD website?
https://www.inspiremd.com
Is InspireMD in the S&P 500?
No, InspireMD is not included in the S&P 500 index
Is InspireMD in the NASDAQ 100?
No, InspireMD is not included in the NASDAQ 100 index
Is InspireMD in the Dow Jones?
No, InspireMD is not included in the Dow Jones index
When was InspireMD the previous earnings report?
No data
When does InspireMD earnings report?
The next expected earnings date for InspireMD is 06 March 2025